在急性缺血性中风中Edaravone的安全概况
Laurence K J Batino1, Cyrus G Escabillas1, Jose C Navarro1
1Department of Neurology, Zeenat Qureshi Stroke Institute, Jose R. Reyes Memorial Medical Center, Manila, Philippines.
Brain and behavior
|December 17, 2024
概括
这项IV期研究发现,静脉注射埃达拉对于菲律宾急性缺血性中风患者来说是安全的. 观察到轻微的副作用,如头痛和头,但没有发生严重的不良事件.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在菲律宾人口中评估静脉注射埃达拉治疗急性缺血性中风的安全性.
- 第四期临床试验从2022年12月到2023年11月进行.
- 主要目标:在14天的edaravone输液期间记录副作用和严重不良事件.
研究的目的:
- 评估菲律宾诊断患有急性缺血性中风的患者静脉注射埃达拉的安全性和耐受性.
- 识别和记录14天内与埃达拉治疗相关的任何不良事件,包括严重的不良事件.
主要方法:
- 获得机构审查委员会的批准和知情同意.
- 纳入标准:18至70岁的患者,在24小时内发生急性缺血性中风.
- 排除标准:极端年龄,怀孕,严重肝功能障碍,其他临床试验参与.
- 埃达拉 (Edaravone) 服用了14天,持续监测和积极记录不良事件.
主要成果:
- 招募了64名患者,58人完成了治疗. 大多数是男性 (n=35),平均年龄为53.5岁,81.03%中度中风严重程度.
- 两名患者报告头痛,一名患者报告头;没有记录任何严重的不良事件.
- 由于低射出分数而导致的中断 (n=2) 显示了正常的实验室和没有副作用;37.93%接受了血栓溶解疗法.
结论:
- 静脉注射埃达拉在菲律宾急性缺血性中风患者中表现出良好的安全性.
- 观察到轻微的副作用 (头痛,头),但不需要停止治疗.
- 这些发现与现有文献一致,支持edaravone的耐受性和潜在的中风管理与警监测.
相关概念视频
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:20Antiepileptic Drugs: Potassium Channel Activators
143
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
143
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
775
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
775
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
453
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
453
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
902
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
902